Nimotuzumab clinical trials
How each study uses nimotuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nimotuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
134 studies that test it; most in 2009 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 13 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 10 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 9 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 10 |
| 2025 | 9 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 121
Biotech Pharmaceutical Co., Ltd. (20) · Sun Yat-sen University (10) · Peking University (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Chinese Academy of Medical Sciences (6) · Tianjin Medical University Cancer Institute and Hospital (6) · Fudan University (5) · YM BioSciences (5)
Often tested with
Tested in the same studies.
Cisplatin (5) · Sintilimab (4) · Irinotecan (3) · Camrelizumab (3) · Toripalimab (3) · Gemcitabine (3) · Tegafur (2) · Gimeracil (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 14, 1 in phase 3
Studies that test nimotuzumab, phase 3 first.
- May 2027Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic CancerPhase 2/3 · Tianjin Medical University Cancer Institute and Hospital
- Nov 2026Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar CancerPhase 2 · Tang-Du Hospital
- Dec 2026Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic CancerPhase 2 · Peking University First Hospital
- Dec 2026SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of ImmunotherapyPhase 2 · The First Affiliated Hospital of Xiamen University
- Jan 2027Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialPhase 2 · Ming-Yuan Chen
- Apr 2027Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell CarcinomaPhase 2 · The First Affiliated Hospital with Nanjing Medical University
- May 2027Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic CancerPhase 2 · Peking Union Medical College Hospital
- May 2027HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D MutationPhase 2 · Zhejiang University
- May 2027A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaPhase 1/2 · Fudan University
- Jun 2027Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2 · Ke Hu
Studies
Open first, then newest update. How each study uses nimotuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 134
- Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Ke HuNCT07821242Written as NimotuzumabHow we know
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingPhase 1/2Zhejiang UniversityNCT07736612Written as NimotuzumabHow we know
- Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual GlioblastomaNot yet recruitingPhase 2Tianjin First Central HospitalNCT07707973Written as nimotuzumabHow we know
- Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingPhase 3Sun Yat-sen UniversityNCT07706985Written as Toripalimab combined with NimotuzumabHow we know
- Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07601737Written as Nimotuzumab InjectionHow we know
- Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2/3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07535567Written as NimotuzumabHow we know
- Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal MalignanciesNot yet recruitingPhase 2Chinese PLA General HospitalNCT07446270Written as Pancreatic cancer: Tunlametinib +NimotuzumabHow we know
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D MutationRecruitingPhase 2Zhejiang UniversityNCT07240766Written as HRS-4642+AG+NimotuzumabHow we know
- Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic CancerEnrolling by invitationPhase 2Peking University First HospitalNCT07386704Written as Nimotuzumab combined with chemoradiotherapyHow we know
- Chemoradiotherapy in Esophageal or Esophagogastric Junction CancerRecruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04821778Written as NimotuzumabHow we know
- Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar CancerRecruitingPhase 2Tang-Du HospitalNCT07353723Written as NimotuzumabHow we know
- Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 3Shandong Cancer Hospital and InstituteNCT07333274Written as NimotuzumabHow we know
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationPhase 2Peking UniversityNCT07312578Written as NimotuzumabHow we know
- Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase IINot yet recruitingPhase 2Fujian Cancer HospitalNCT07310771Written as Sintilimab combined with chemotherapy and nimotuzumabHow we know
- Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07277452Written as NimotuzumabHow we know
- Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06509009Written as NimotuzumabHow we know
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as NimotuzumabHow we know
- A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaRecruitingPhase 1/2Fudan UniversityNCT07105592Written as Nimotuzumab+Adebrelimab+ChemotherapyHow we know
- An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder CancerNot yet recruitingPhase 1Peking University First HospitalNCT07053735Written as Nimotuzumab and RadiotherapyHow we know
- SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of ImmunotherapyRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06676722Written as SBRT combined with Nimotuzumab followed by TislelizumabHow we know
See all 134 studies that test nimotuzumab →
Given beside what is tested · 6 — nimotuzumab is usual care or a partner of the new treatment
- HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsRecruitingPhase 2Zhejiang UniversityNCT06770452Written as NimotuzumabHow we know
- Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaRecruitingPhase 3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07445048Written as NimotuzumabHow we know
- Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07457528Written as NimotuzumabHow we know
- Neoadjuvant Treatment Modalities in Esophageal CancerRecruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04821843Written as NimotuzumabHow we know
- A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid TumorsRecruitingPhase 2Suzhou Genhouse Bio Co., Ltd.NCT06322095Written as EGFR Monoclonal antibodyHow we know
- HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 1/2West China HospitalNCT06773130Written as NimotuzumabHow we know
Codes
What other systems call nimotuzumab · ClinicalTrials.gg INT004790
- MeSH (NLM) C501466nimotuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6NS400BXKHNIMOTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3877039nimotuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2733NimotuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C501466 | nimotuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6NS400BXKH | NIMOTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3877039 | nimotuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2733 | Nimotuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.